Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease

International Journal of Cancer

Volumn 80, Issue 2, 1999, Pages 240-249

  Dolcetti, Riccardo ^a   Quaia, Michele ^a   Gloghini, Annunziata ^a   De Re, Valli ^a   Zancai, Paola ^a   Cariati, Roberta ^a   Babuin, Laura ^a   Cilia, Anna Maria ^a   Rizzo, Silvana ^a   Carbone, Antonino ^a   Boiocchi, Mauro ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B LYMPHOCYTE; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; VIRUS CARCINOGENESIS;

ANIMALS; B-LYMPHOCYTES; CELL DIVISION; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HISTOCYTOCHEMISTRY; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MICE; MICE, NUDE; MIDDLE AGED; TUMOR STEM CELL ASSAY;

EID: 0033579878     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990118)80:2<240::AID-IJC13>3.0.CO;2-J     Document Type: Article

References (36)

1. BAER, R., BANKIER, A.T., BIGGIN, M.D., DEININGER, P.L., FARRELL, P.J., GIBSON, T.J., HATFULL, G., HUDSON, G.S., SATCHWELL, S.C., SEGUIN, C., TUFFNELL, P.S. and BARRELL, B.G., DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (Lond.), 310, 207-211 (1984).
2. CHEN, M.L., TSAI, C.N., LIANG, C.L., SHU, C.H., HUANG, C.R., SULITZEANU, D., LIU, S.T. and CHANG, Y.S., Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene, 7, 2131-2140 (1992).
3. COHEN, J.I., PICCHIO, G.R. and MOSTER, D.E., Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro. J. Virol., 66, 7555-7559 (1992).
4. COHEN, J.I., WANG, F. and KIEFF, E., Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J. Virol., 65, 2545-2554 (1991).
5. DE RE, V., BOIOCCHI, M., DE VITA, S., DOLCETTI, R., GLOGHINI, A., UCCINI, S., BARONI, C., SCARPA, A., CATTORETTI, G. and CARBONE, A., Subtypes of Epstein-Barr virus in HIV-1-associated and HIV-1-unrelated Hodgkin's disease cases. Int. J. Cancer. 54, 895-898 (1993).
6. DOLCETTI, R., ZANCAI, P., DE RE, V.,GLOGHINI, A., BIGONI, B., PIVETTA, B., DE VITA, S., CARBONE, A. and BOIOCCHI, M., Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood, 89, 1723-1731 (1997).
7. GRATAMA, J.W. and ERNBERG, I., Molecular epidemiology of Epstein-Barr virus infection. Adv. Cancer Res., 67, 197-255 (1995).
8. GRUSS, H.J. and DOWER, S.K., Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood, 85, 3378-3404 (1995).
9. HAMMERSCMIDT, W., SUGDEN, B. and BAICHWAL, V.R., The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J. Virol., 53, 2469-2475 (1989).
10. HU, L.F., CHEN, F., ZHENG, X., ERNBERG. I., CAO, S.L., CHRISTENSSON, B., KLEIN, G. and WINBERG, G., Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMPI. Oncogene, 8, 1575-1583 (1993).
11. HU, L.F., ZABAROVSKY, E.R., CHEN, F., CAO, S.L., ERNBERG, I., KLEIN, G. and WINBERG, G., Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J. gen. Virol., 72, 2399-2409 (1991).
12. JENKINS, P.J. and FARRELL, P.J., Are particular Epstein-Barr virus strains linked to disease? Semin. Cancer Biol., 7, 209-215 (1996).
13. KAYE, K.M., IZUMI, K.M., MOSIALOS, G. and KIEFF, E., The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J. Virol., 69, 675-683 (1995).
14. KHANIM, F., YAO. Q.Y., NIEDBITEK, G., SIHOTA, S., RICKINSON, A.B. and YOUNG, L.S., Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood, 88, 3491-3501 (1996).
15. KLEIN, C., ROTHENBERGER, S., NIEMEYER, C., BACHMANN, E., ODERMATT, B., BOHM, N., BRANDIS, M. and KNECHT, H., EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. Brit. J. Haematol., 91, 938-940 (1995).
16. KNECHT, H., BACHMANN, E., BROUSSET, P., ROTHENBERGER, S., EINSELE, H., LESTOU, V.S., DELSOL, G., BACHMANN, F., AMBROS, P.F. and ODERMATT, B.F., Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene, 10, 523-528 (1995).
17. KNECHT, H., BACHMANN, E., BROUSSET, P., SANDVEJ, K., NADAL, D., BACHMANN, F., ODERMATT, B.F., DELSOL, G. and PALLESEN, G., Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood, 82, 2937-2942 (1993).
18. KNECHT, H. and 13 OTHERS, Deletion variants within the NF-kappa B activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations. Blood, 87, 876-881 (1996).
19. LARCHER, C., FEND, F., MITTERER, M., PRANG, N., SCHWARZMANN, F. and HUEMER, H.P., Role of Epstein-Barr virus and soluble CD21 in persistent polyclonal B-cell lymphocytosis. Brit. J. Haematol., 90, 532-540 (1995).
20. LARCHER, C., MCQUAIN, C., BERGER, C, MITTERER, M., QUESENBERRY, P.J., HUEMER, H.P. and KNECHT, H., Epstein-Barr virus-associated persistent polyclonal B-cell lymphocytosis with a distinct 69-base pair deletion in the LMP1 oncogene. Ann. Hematol., 74, 23-28 (1997).
21. LI, S.N., CHANG, Y.S. and LIU, ST., Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene, 12, 2129-2135 (1996).
22. LUNG, M.L. CHANG, R.S., HUANG, M.L., GUO, H.Y., CHOY, D., SHAM, J., TSAO, S.Y. CHENG, P. and NG, M.H., Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in southern China. Virology, 176, 44-53 (1990).
23. MEHL, A.M., FISHER, N., ROWE, M., HARTMANN, F., DAUS, H., TRUMPER, L., PFREUNDSCHUH, M., MÜLLER-LANTZSCH, N. and GRÄSSER, F.A., Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr virus (EBV)-encoded latent membrane protein-1 (LMP-1) from a single Hodgkin's lymphoma. Int. J. Cancer. 76, 194-200 (1998).
24. MITCHELL, T. and SUGDEN, B., Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J. Virol., 69, 2968-2976 (1995).
25. MOSIALOS, G., BIRKENBACH, M., YALAMANCHILI, R., VANARSDALE, T., WARE, C. and KIEFF, E., The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 80, 389-399 (1995).
26. PENG, M. and LUNDGREN, E., Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene, 7, 1775-1782 (1992).
27. RICKINSON, A.B. and KIEFF, E., Epstein-Barr virus. In: B.N. Fields, D.M. Knipe and P.M. Howley (eds.), Fields virology (3rd ed.). Lippincott-Raven Publishers, Philadelphia (1995).
28. ROTHENBERGER, S., BACHMANN, E., BERGER, C., MCQUAIN, C., ODERMATT, B.F. and KNECHT, H., Natural 30 base pair and 69 base pair deletion variants of the LMP-1 oncogene do stimulate NF-κB-mediated transcription. Oncogene, 14, 2123-2126 (1997a).
29. ROTHENBERGER, S., BACHMANN E. and KNECHT, H., Molecular and functional analysis of the Epstein-Barr virus LMP-1 oncogene promoter in lymphoproliferative diseases. Exp. Hematol., 25, 1326-1332 (1997b).
30. SANDVEJ, K., MUNCH, H. and HAMILTON-DUTOIT, S., Mutations in the Epstein-Barr virus latent membrane protein-1 (BNLF-1) gene in spontaneous lymphoblastoid cell lines: effect on in vitro transformation associated parameters and tumorigenicity in SCID and nude mice. J. clin. Pathol. mol. Pathol. 49, M290-M297 (1996).
31. SANDVEJ, K., PEH, S.C., ANDRESEN, B.S. and PALLESEN, G., Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood, 84, 4053-4060 (1994).
32. SANTÓN, A., MANZANAL, A., CAMPO, E. and BELLAS, C., Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease. J. clin. Pathol. mol. Pathol., 48, M184-M187 (1995).
33. SCHUSTER, V., OTT, G., SEIDENSPINNER, S. and KRETH, H.W., Common Epstein-Barr virus (EBV) type-1 variant strains in both malignant and benign EBV-associated disorders. Blood, 87, 1579-1585 (1996a).
34. SCHUSTER, V., SEIDENSPINNER, S. and KRETH, H.W., Detection of a nuclear antigen 2 (EBNA2)-variant Epstein-Barr virus strain in two siblings with fatal lymphoproliferative disease. J. med. Virol., 48, 114-120 (1996b).
35. TRIVEDJ, P., Hu, L.F., CHEN, F., CHRISTENSSON, B., MASUCCI, M.G., KLEIN, G. and WINBERG, G., Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Europ. J. Cancer, 30A, 84-88 (1994).
36. WANG, F., GREGORY, C., SAMPLE, C., ROWE, M., LIEBOWITZ, D., MURRAY, R., RICKINSON, A. and KIEFF, E., Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol., 64, 2309-2318 (1990).